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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine “Does Metformin use
during pregnancy effectively reduce the rate of early pregnancy loss in women with polycystic ovary
syndrome?”
STUDY DESIGN: This review is based on two primary double-blind, randomized controlled trials and
a prospective controlled trial that was not randomized or blinded to evaluate whether metformin, a
medication used to manage PCOS, can also prevent early pregnancy loss in women with PCOS.
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and located
through PubMed, OVID and COCHRANE databases..
OUTCOMES MEASURED: Each of the three trials included evaluated the effectiveness of
metformin at preventing pregnancy loss and premature labor in patients with PCOS, as well as safety of
administering the drug during pregnancy. Sohrabvand et al solely focused on early pregnancy loss, with
other studies following pregnancy to term.
RESULTS: Two double-blind randomized controlled trials and one prospective controlled trial were
included in this review. Results from the Vanky et al (2004) study demonstrated a 22.7% decrease in
premature birth rate in metformin group as compared to control. Sohrabvand et al also presented a
statistically significant decrease in current miscarriage rate in groups taking metformin up to 8 weeks
and 12 weeks, of gestation (p = 0.008 and p = 0.002, respectively) as compared to previous miscarriage
rate. Vanky et al (2010) analyzed a multicenter trial, but its results differed in that a statistically
significant decrease in preterm labor could only be appreciated after a subgroup analysis was
performed of participants deemed to have good and acceptable compliance (7.4% decrease, p = 0.03).
The recommendation made in this last trial was not in favor of metformin usage due to a perceived
overall lack of benefit.
CONCLUSIONS: Two of the three trials in this review support the use of metformin during
pregnancy in women with PCOS as means of preventing pregnancy loss or premature labor. Various
factors, such as tighter monitoring throughout pregnancy, and inconsistencies in pre-pregnancy
metformin intake could have affected the results within this patient population.
KEY WORDS: polycystic ovary syndrome, miscarriage, pregnancy

Prikhodko: Metformin & Pregnancy Loss in PCOS 1

INTRODUCTION
Polycystic ovary syndrome (PCOS) is otherwise known as Stein Leventhal Syndrome. It carries
no specific predilection for race or ethnicity, and is a multifactorial disorder characterized by
anovulation, polycystic ovaries, insulin resistance, and hyperandrogenism.1 It can result in numerous
complications, and one of them, early pregnancy loss, is the focus of this paper.2 This paper is primarily
based on two double-blind, randomized controlled trials and a prospective controlled trial that was not
randomized or blinded to evaluate whether metformin, a medication used to manage PCOS, can also
prevent early pregnancy loss in women with PCOS.
PCOS and its related complications are relevant to the Physician Assistant practicing today due
to the vast proportion of female patients plagued by the disorder. Based on data from 2003-2008, the
number of PCOS-related doctor office visits reached an astounding total of 2,328,000 visits, with a
mean yearly number of 516,000 visits.3 Because of these factors, PCOS has also proved to be quite an
expensive condition to manage. The most recent data regarding cost of PCOS-related complaints spans
the period between 2003-2008, and demonstrated a total cost of $1.16 billion annually.3 Overall, PCOS
affects 5-10% of the female population in the US, a pretty significant percentage, especially when its
consequences and related disorders are considered: diabetes mellitus, infertility, metabolic syndrome,
and cardiovascular disease. Early pregnancy loss is the focus in this paper, and is also a frustrating
aspect of PCOS, as becoming pregnant alone can prove to be quite a challenge.1
The exact cause of PCOS is unknown, but it has been attributed to a pattern of genetic
inheritance, as it tends to be seen more frequently among relatives.1 The role of PCOS in leading to
infertility, as well as early pregnancy loss, is multifactorial and is strongly believed to be caused by the
combination of hyperandrogenism, alterations in gonadotropin secretion, and the insulin resistance,
among other things.4
In treatment of PCOS, initially a trial of diet and exercise aimed at weight loss is recommended,
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as women with PCOS are typically overweight. Often, achieving a healthy weight is enough to relieve
some of the symptoms associated with the disorder. If poorly controlled by diet and exercise, insulin
resistance is managed with metformin, and frequently has favorable outcomes in restoring ovulation as
well.1 If additional help is needed for stimulation of ovulation, clomiphene citrate can be used.1
Management of potential cardiovascular and metabolic syndrome complications is addressed as well in
the form of pushing for weight loss, and supplementing with pharmacotherapy as deemed appropriate.1
Often, the above mentioned treatments are enough to adequately manage the disorder. However,
it is widely known that even with appropriate management, women with PCOS often have a very hard
time achieving a pregnancy. As if that were not enough, maintaining that pregnancy can additionally
prove to be futile, as early pregnancy loss is quite common in these patients.5 Numerous interventions
have been looked at as a potential 'remedy' for prevention of this complication, but not many have
shown success. The studies evaluated in this paper demonstrate that metformin, a drug given to manage
anovulation and hyperinsilunemia in PCOS, can be continued after the patient becomes pregnant and
has actually shown a positive outcome related to maintenance of the pregnancy.5
OBJECTIVE
The objective of this selective EBM review is to determine “Does Metformin use during
pregnancy effectively reduce the rate of early pregnancy loss in women with polycystic ovary
syndrome?”
METHODS
The studies that were used to answer this question all fit the following criteria: the populations
studied consisted of women of reproductive age, 18-45 years old, and diagnosed with PCOS, who also
had a confirmed viable pregnancy. The intervention used was a dose range of Metformin 500-850mg
given three times a day to the treatment group. The comparison group in the studies received a visually
matched placebo. Additionally, previous history of miscarriages in these women was used for
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comparison with the outcomes after the trial with metformin. Outcomes that were measured surrounded
the efficacy of metformin in helping to maintain a viable pregnancy past the first trimester without
complications or pregnancy loss. Types of studies used in this systematic review included two doubleblind, randomized controlled trials and a prospective controlled trial that was not randomized or
blinded.
Key words that were used in searching for appropriate studies included metformin, pregnancy
and PCOS. All articles used were published in English, in peer-reviewed journals, and located through
PubMed, OVID and COCHRANE databases. The articles/studies were researched by the author, and
selected based on the type of trial conducted, focus on patient-oriented outcomes (POEMs), and of
course their direct relevance to the clinical question presented. Inclusion criteria for the systematic
review included randomized, controlled, double-blind studies, as well as controlled trials that were not
randomized, included POEMs, and had a publish date after 1996. Exclusion criteria included studies
that were comparing metformin with other drugs in prevention of pregnancy loss in PCOS, or using
metformin in combo with another drug. Reluctance to take drugs during pregnancy, known alcohol
abuse, previous diagnosis of diabetes mellitus, and treatment with oral glucocorticoids or other drugs
known to interfere with metformin were exclusion criteria for the subjects recruited for the studies.
Summary of statistics that were reported or used were relative risk reduction (RRR), absolute risk
reduction (ARR), number needed to treat (NNT), confidence intervals, and p-values.
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Demographics and characteristics of the studies utilized for this review are displayed in Table 1.
Table 1. Demographics and characteristics of included studies
Study

Type

# Pts

Age

Inclusion Criteria

Exclusion Criteria

40

28-33

Diagnosis of PCOS
before the actual
pregnancy; Age 1840 years old;
Gestational age
between 5 and 12
weeks

Liver disease;
2
Creatinine >130mmol/l
Known alcohol abuse;
History of diabetes
mellitus; Fasting
plasma glucose >5.6
mmol/l; Treatment
with oral
glucocorticoids or use
of drugs known to
interfere with
metformin

Randomized to
receive metformin
(850mg) or visually
matched placebo
BID initiated with
diagnosis of
pregnancy and
continued throughout
gestation

Vanky5, 2010 Double
257
blind,
placebo
controlled
multicenter
RCT

18-42

PCOS diagnosed
according to the
Rotterdam criteria;
Age 18-45 yrs;
Gestational age
between 5 and 12
weeks;
A singleton viable
fetus shown on
ultrasonography

Alanine
12
aminotransferase
higher than 90 IU/liter;
Serum creatinine
concentration higher
than 1.70 mg/dl;
Known alcohol abuse;
Previously diagnosed
diabetes mellitus or
fasting serum glucose
higher than 126 mg/dl
at the time point of
inclusion; Treatment
with oral
glucocorticoids, or use
of drugs known to
interfere with
metformin

Randomized to
receive metformin
(500 mg) or visually
matched placebo
BID

Sohrabvand7,
2009

22-33

Pregnant women with Reluctance to take
history of infertility
drugs during
that was solely due to pregnancy
PCOS, based on
Rotterdam
criteria and
confirmed by
physician; Received
metformin along with
other ovulationinducing drugs prior
to pregnancy

6

Vanky , 2004 Double
blind,
placebo
controlled
RCT

RCT

75

W/D Interventions

0

Randomized to
receive metformin
(500mg TID) until 56 weeks gestation in
in Group A, 8 weeks
gestation in Group B,
and until 12 weeks of
gestation in Group
C., after which it was
entirely
discontinued.
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OUTCOMES MEASURED
Of the various outcomes assessed in these trials, the ability of maintaining a pregnancy past the
first trimester in women with PCOS taking metformin, as well as adverse reactions associated with
taking the drug were the main point of focus. All outcomes were based on patient-oriented evidence
that mattered (POEMs). Vanky et al (2004) initially compared the incidence of pregnancy
complications in women with PCOS who were taking metformin with those who took an identically
matched placebo, including premature delivery, gestational diabetes mellitus (GDM) and thrombotic
events.6 Sohrabvand et al compared the occurrence of miscarriage among three separate groups of
participants which either discontinued metformin after diagnosis of pregnancy, continued taking it until
week 8 of gestation, or week 12 of gestation.7 The study additionally compared previous history of
miscarriage in the participants with its occurrence during the trial. Vanky et al (2010) compared
metformin and placebo groups in terms of the occurrence of premature delivery or miscarriage,
preeclampsia, new GDM, and other complications of pregnancy.5
RESULTS
Among all trials used in this review, dichotomous data was used to assess the outcomes
measured. In the first trial by Vanky et al (2004) it was discovered that the only cases of pre-term
delivery occurred within the placebo group, with no cases of miscarriages or preterm delivery
occurring within the metformin group.6 (Table 2) Table 2 also demonstrates that there was no statistical
difference among the patient characteristics in the two groups, including their previous history of
miscarriage. Whereas no p-value was provided for this significant finding, the RRR was calculated to
be 100%, ARR was 22%, and NNT was 5 patients (Table 3). This NNT suggests that for every 5
patients treated with 850mg of Metformin once daily for first week and twice daily for all subsequent
weeks of pregnancy, preterm delivery would be prevented in one additional woman with PCOS, than
when treated with placebo. This study additionally suggested that metformin is safe in pregnancy, as it
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did not appear to contribute to any severe pregnancy complications. A statistically significant p-value
of 0.01 supports this conclusion, as 32% of women within the control group suffered severe pregnancy
or post-partum complications, with complete absence of these complications in the metformin group.6
There were 2 drop-outs from this trial, one due to inconvenient traveling distance, and the other due to
motivation failure; none withdrew due to complications or intolerance of metformin.6
Table 2. Selected patient characteristics at inclusion and results of trial 6
Metformin

Placebo

P

18

22

–

# of Former Pregnancies (%)

11 (61)

11 (50)

0.8

# of Former Pregnancy Losses (%)

7 (39)

10 (54)

0.5

Metformin Treatment at Conception (%)

8 (44)

11 (50)

0.7

Gestational age at birth in days (SD)

282 (8)

266 (36)

0.06

0 (0)

5 (23)

–

# of Participants

# of Pre-term deliveries (%)

Table 3. Analysis of efficacy of Metformin in prevention of preterm labor in PCOS

Vanky6, 2004

Relative risk reduction
(RRR)

Absolute risk reduction
(ARR)

Number needed to treat
(NNT)

100%

1/.22

4.54 = 5 patients

Sohrabvand et al stratified its participants into three groups based on the clinic in which they
were initially interviewed.6 There were 25 participants within each group, and none dropped out.
Conception within this patient population was assisted with a regimen of clomiphene citrate and
1500mg metformin daily. Aside from comparison of the trial outcomes of each group, previous history
of miscarriage was additionally compared with miscarriage occurrences during the trial. Within Group
A, among participants who discontinued the metformin upon diagnosis of pregnancy, there was 1
miscarriage compared with 6 former pregnancy losses, demonstrating a statistically insignificant pvalue of 0.06. Group B was administered metformin until the 8th week of gestation, and resulted in 1
miscarriage compared with a history of 8 total pregnancy losses among the group. Group C continued
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taking metformin until week 12 of gestation, and resulted in 2 miscarriages compared with a history of
10 total miscarriages. The p-values for both Group B and C were statistically significant at 0.008 and
0.002, respectively(Table 4). These findings demonstrated the efficacy of metformin on two separate
levels, as it appears to have reduced miscarriage history within the individual groups, as well as within
the groups that continued taking metformin after the diagnosis of pregnancy.7
Table 4. Patient Characteristics at Inclusion and Results of Trial7
Group 1

Group 2

Group 3

P value

25

25

25

–

27.96 (5.7)

28.72 (3.57)

26.8 (3.88)

0.115

Group 1

Group 2

Group 3

# of Former Pregnancy Losses (%)

6 (20)

8 (32)

10 (40%)

# of Current Miscarriage (%)

1 (4)

1 (4)

2 (8)

P value

0.06

0.008

0.002

# of Participants
Age (SD)
Results

Vanky et al (2010), a randomized controlled multicenter study, initially recruited 364
participants for its trial, however, 32 were excluded due to inability to meet inclusion criteria, and 58
did not desire participation. Following randomization, a single participant from the experimental group
was additionally excluded due to a 21-hydroxylase deficiency diagnosis.5 Within the placebo group 3
patients were lost to follow-up due to miscarriages, resulting in a total of 135 participants within each
arm of the trial. Primary endpoints of this trial included preterm delivery, and demonstrated a reduction
of preterm delivery rate from 8.2% within the placebo group to 3.7% within the experimental arm, a
finding that was determined to be not statistically significant (p = 0.12) (Table 5). However, of the 270
participants within the study, 80.2%, or 216 women, were determined to have good and acceptable
compliance, resulting in performance of a per protocol analysis.5 The analysis showed a statistically
significant (p = 0.03) decrease in preterm birth occurrence among the two groups, demonstrating a
7.4% decrease (CI=0.9–1.2), as compared with the previous 4.5% (CI=-10.1–1.2 ). RRR was calculated
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to be 73%, ARR was 7.4%, and NNT was 14 patients, indicating that 14 pregnant women with PCOS
would have to be treated with metformin to successfully prevent preterm labor in one additional
woman (Table 6). No differences could be appreciated between the two groups in terms of
preeclampsia and GDM in either the primary endpoints or the per protocol subgroup analysis, as
demonstrated by p-values that were all statistically insignificant.5
Table 5.
Preterm Delivery / Miscarriage
Occurrence

Metformin (%)

Placebo (%)

95% CI

P value

Primary endpoints

5/135 (3.7)

11/135 (8.2)

-10.1–1.2

0.12

Subgroup analysis

3/108 (2.8)

11/108 (10.2)

0.9–13.9

0.03

Table 6. Analysis of efficacy of Metformin in prevention of preterm labor in PCOS

Vanky6, 2010

Relative risk reduction
(RRR)

Absolute risk reduction
(ARR)

Number needed to treat
(NNT)

73%

1/.074

13.5 = 14 patients

DISCUSSION
Metformin is a drug belonging to the biguanide class, and is most widely known as the
antidiabetic drug used in management of Type 2 diabetes mellitus. It was initially created to help
control blood glucose levels in diabetics, however its use today spans across a spectrum of disorders
involving insulin resistance.8 Metformin's mechanism of action mainly involves decreasing hepatic
glucose production, however it also increases insulin sensitivity and glucose metabolism within certain
organs and tissues, such as muscle, liver, and intestine. Within the intestine this metabolism results in a
byproduct, lactate, which is typically taken up by the liver and used in the process of hepatic
gluconeogenesis. The exact molecular mode of action of metformin is not certain, but known to
involve the enzyme AMP-activated protein kinase (AMPK), Peutz-Jeghers protein, and LKB1. In
addition to those mechanisms, metformin is also known to promote lowering of lipid levels and aiding
in weight loss and management. Its action at decreasing blood glucose levels, managing insulin
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resistance, and also decreasing androgen levels is believed to be the key in helping to manage PCOSrelated complications such as anovulation and infertility5 ,7.
Perhaps the most common side effects of metformin are gastrointestinal in nature, and include
abdominal discomfort, nausea, possible vomiting, diarrhea, and a metallic taste in the mouth8. Vanky et
al (2010) mentioned diarrhea and bloating as being more prevalent within the metformin group, with
abdominal discomfort and nausea being equally prevalent5 . Vanky et al (2004) also mentioned nausea
and abdominal discomfort as being equally prevalent among the two groups, however no participants
dropped out of the study due to the side effects, and were instead told to take half the original dose of
metformin5 .
Another side effect of metformin is lactic acidosis, and although it may mimic the
gastrointestinal side effects, it is much more serious8. Symptoms include abdominal pain, nausea,
vomiting, hypotension, and hyperventilation8. Metformin contributes to this condition in two ways: by
increasing lactate production in the intestine, as previously mentioned, and by decreasing hepatic
uptake of lactate8. This complication, however, is more associated with metformin overdose, kidney,
lung, and liver disease, and wasn't present in any of the trials included in this review8..
Sohrabvand et al study was perhaps the only one in this review to directly address the effect of
metformin on early pregnancy loss, as both of the Vanky et al trials looked at premature birth as a
potential complication of pregnancy, and addressed other effects of metformin in pregnancy.
Regardless of the initial trial goal, the final results of all the studies included in this review point to a
favorable outcome, as metformin appears to have decreased the incidence of both early pregnancy loss
and premature birth in the participants, as long as compliance with treatment was a factor. However, the
largest of the three trials, Vanky et al (2010), does not conclude that there is a worthy “benefit of the
drug on study endpoints, and speaks against this practice.”5 The supposed benefit of metformin here
was only evident in the fewer number of preterm births after the subgroup analysis was performed,
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with absolutely no statistically significant difference in either the primary endpoints analysis or the
subgroup analysis of other pregnancy complications.5 The authors therefore attributed the supposed
benefit to a “tight and thorough pregnancy follow-up and...diet and lifestyle intervention.”5 The smaller
trials did attribute the reduction in preterm births and miscarriage to metformin, however, the sample
size was cited as not adequately large enough to conclude the definitive benefit. Worthy of mention is
the finding that metformin treatment appears to be safe in pregnant women with PCOS among all three
trials.5,6,7
There are limitations to this study which lead to a potential doubt about the certainty of
metformin as playing a definitive role in prevention of early pregnancy loss. One limitation is that all
participants in the trials received comprehensive counseling and health care throughout the duration of
the trial. This comprehensive health care and follow-up is not necessarily provided to all women
receiving prenatal care outside the scope of the trials, and may have contributed to a better outcome of
the pregnancy. Additionally the results may have been skewed by a either a more intense disease course
or a milder one of study participants, as compared to other women with PCOS. Yet another factor
consider is pre-pregnancy therapy with metformin, and the different times and gestational ages at
which metformin therapy was initiated.
CONCLUSIONS
Among the data presented in the three trials used for this review metformin appears to be
effective in reducing early pregnancy loss in women with PCOS. However there are inconsistencies
present in data interpretations within these trials, which calls for more investigation to be performed.
Benefits of metformin have been proven in non-pregnant patients with PCOS, and metformin does
appear to be safe in pregnancy, which has facilitated its use during pregnancy regardless of its
inconsistent pattern of benefits. Perhaps an entirely separate recommendation could be made to
increase the quality of prenatal care among women with PCOS, as this was cited as a possible hidden
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“benefit” of metformin. Future studies should be performed to additionally evaluate the benefit of
metformin in preventing pregnancy loss or premature delivery, and should further refine the study
population by including women who have a similar pre-pregnancy history with metformin
administration, and in whom metformin is initiated preconception and continued through the diagnosis
of pregnancy. Compliance with treatment should be strongly encouraged to maximize the consistency
of data results.
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